Total Payments
$205,779
2024 Payments
$20,351
Companies
10
Transactions
98
Medicare Patients
446
Medicare Billing
$108,224
Payment Breakdown by Category
Consulting$134,216 (65.2%)
Research$35,151 (17.1%)
Other$28,046 (13.6%)
Travel$6,406 (3.1%)
Food & Beverage$1,961 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $134,216 | 34 | 65.2% |
| Unspecified | $35,151 | 8 | 17.1% |
| Honoraria | $16,230 | 6 | 7.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,816 | 9 | 5.7% |
| Travel and Lodging | $6,406 | 24 | 3.1% |
| Food and Beverage | $1,961 | 17 | 1.0% |
Payments by Type
General
$170,628
90 transactions
Research
$35,151
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59,583 | 34 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $38,690 | 18 | $0 (2024) |
| Celgene Corporation | $34,469 | 18 | $0 (2022) |
| EUSA Pharma (US) LLC | $24,405 | 12 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $23,000 | 1 | $0 (2019) |
| RECORDATI_RARE_DISEASES_INC. | $10,629 | 6 | $0 (2024) |
| Blueprint Medicines Corporation | $7,804 | 2 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $5,465 | 5 | $0 (2017) |
| Genentech USA, Inc. | $1,650 | 1 | $0 (2020) |
| PFIZER INC. | $85.36 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,351 | 11 | RECORDATI_RARE_DISEASES_INC. ($10,629) |
| 2023 | $23,752 | 4 | E.R. Squibb & Sons, L.L.C. ($19,909) |
| 2022 | $25,779 | 7 | Celgene Corporation ($16,668) |
| 2021 | $29,537 | 13 | EUSA Pharma (US) LLC ($14,435) |
| 2020 | $16,738 | 9 | Novartis Pharmaceuticals Corporation ($7,423) |
| 2019 | $50,511 | 20 | Novartis Pharmaceuticals Corporation ($24,686) |
| 2018 | $22,561 | 18 | Celgene Corporation ($11,502) |
| 2017 | $16,550 | 16 | E.R. Squibb & Sons, L.L.C. ($11,085) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,390.00 | General |
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,384.00 | General |
| 09/10/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Consulting Fee | Cash or cash equivalent | $2,075.50 | General |
| Category: Hematology | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $847.50 | General |
| 07/31/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Honoraria | Cash or cash equivalent | $5,440.00 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/30/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Honoraria | Cash or cash equivalent | $1,360.00 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/23/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $771.79 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/23/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Travel and Lodging | Cash or cash equivalent | $336.95 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 04/30/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Honoraria | Cash or cash equivalent | $1,360.00 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 04/10/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Honoraria | Cash or cash equivalent | $1,360.00 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 10/05/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 06/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $15,820.00 | General |
| 04/14/2023 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $3,843.75 | General |
| 01/25/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,012.50 | General |
| 11/01/2022 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $85.36 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/02/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | SCEMBLIX (Drug) | — | In-kind items and services | $320.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 06/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | TASIGNA (Drug) | — | In-kind items and services | $3,019.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: HEMATOLOGY | ||||||
| 06/29/2022 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| 04/27/2022 | EUSA Pharma (US) LLC | Sylvant (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: Hematology | ||||||
| 03/14/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $14,690.00 | General |
| 03/14/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,977.50 | General |
| 10/29/2021 | EUSA Pharma (US) LLC | Sylvant (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Hematology | ||||||
| 10/15/2021 | EUSA Pharma (US) LLC | Sylvant (Drug) | Consulting Fee | Cash or cash equivalent | $4,250.00 | General |
| Category: Hematology | ||||||
| 08/31/2021 | EUSA Pharma (US) LLC | Sylvant (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PNH Registry | Alexion Pharmaceuticals, Inc. | $23,000 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $3,339 | 2 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $3,275 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR TASIGNA RESEARCH | Novartis Pharmaceuticals Corporation | $2,813 | 1 |
| AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $1,524 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,200 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 81 | 226 | $116,708 | $20,232 |
| 2022 | 4 | 111 | 348 | $161,479 | $28,486 |
| 2021 | 6 | 149 | 373 | $177,648 | $33,067 |
| 2020 | 4 | 105 | 325 | $160,047 | $26,438 |
Total Patients
446
Total Services
1,272
Medicare Billing
$108,224
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 92 | $55,936 | $8,429 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 41 | 75 | $44,325 | $7,996 | 18.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 26 | 59 | $16,447 | $3,807 | 23.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 173 | $95,669 | $13,726 | 14.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 32 | 67 | $35,979 | $7,306 | 20.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 38 | 97 | $24,056 | $6,563 | 27.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 11 | $5,775 | $890.74 | 15.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 165 | $88,605 | $13,487 | 15.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 57 | 120 | $62,505 | $13,382 | 21.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 23 | 38 | $9,424 | $2,884 | 30.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 16 | 18 | $9,180 | $1,494 | 16.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 13 | 13 | $4,799 | $945.24 | 19.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 13 | 19 | $3,135 | $874.69 | 27.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 165 | $85,965 | $13,711 | 15.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 55 | 128 | $64,768 | $10,771 | 16.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 18 | $4,372 | $1,132 | 25.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 12 | 14 | $4,942 | $825.22 | 16.7% |
About Dr. Sudipto Mukherjee, MD
Dr. Sudipto Mukherjee, MD is a Internal Medicine healthcare provider based in Royal Oak, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861692527.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sudipto Mukherjee, MD has received a total of $205,779 in payments from pharmaceutical and medical device companies, with $20,351 received in 2024. These payments were reported across 98 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($134,216).
As a Medicare-enrolled provider, Mukherjee has provided services to 446 Medicare beneficiaries, totaling 1,272 services with total Medicare billing of $108,224. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Royal Oak, MI
- Active Since 07/20/2007
- Last Updated 07/20/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1861692527
Products in Payments
- TASIGNA (Drug) $35,022
- Sylvant (Drug) $24,405
- SOLIRIS (Drug) $23,000
- SYLVANT (Drug) $10,629
- Luspatercept (Drug) $9,839
- KISQALI (Drug) $8,439
- EMPLICITI (Biological) $6,541
- OPDIVO (Biological) $4,510
- ONUREG (Drug) $3,474
- REBLOZYL (Biological) $2,076
- VENCLEXTA (Biological) $1,650
- CC-486 (Drug) $1,524
- SCEMBLIX (Drug) $320.00
- BOSULIF (Drug) $85.36
- SPRYCEL (Drug) $33.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Royal Oak
Dr. Ryan Madder, M.d, M.D
Internal Medicine — Payments: $157,098
Internal Medicine $157,098
Dr. Mohamad Rasm Alsibae, Md, MD
Internal Medicine — Payments: $122,437
Internal Medicine $122,437
Nishaki Mehta, M.d, M.D
Internal Medicine — Payments: $84,717
Internal Medicine $84,717
Niharika Samala, Md, MD
Internal Medicine — Payments: $29,942
Internal Medicine $29,942
Shanu Agarwal, Md, MD
Internal Medicine — Payments: $22,785
Internal Medicine $22,785
Bhavinkumar Dalal, Md, MD
Internal Medicine — Payments: $21,864
Internal Medicine $21,864